Commercial insight into the pharma and biotech sector.
EvaluatePharma and EP Vantage in the Press - archive
January 2011
This is the sector to back for the next decade - MoneyWeek, Jan 17, 2011
"...EvaluatePharma projects that biologics (genetically engineered drugs) will account for 50% of the top 100 drugs in 2014..." more...
December 2010
AstraZeneca takes $445m hit to halt motavizumab licence application - InPharm, December 22, 2010
"AstraZeneca has withdrawn a US licence application for its biologic respiratory treatment motavizumab in a move that will cost the company $445 million...
The company...said this will have no impact on its share earnings guidance for 2010. But the move is still a blow to the firm - motavizumab was forecast by analysts at EvaluatePharma to make over $5 billion a year by 2016..." more...
[note- in April 2010, EvaluatePharma calculated the NPV of motavizumab to AstraZeneca to be more than $5 billion.]
New Life Science Companies- Boston City TV (via YouTube), Dec 2, 2010
"Mayor Menino welcomes Evaluate Pharma and other new life science companies to Boston with a ribbon cutting ceremony. November 11, 2010.." more...
November 2010
Mayor Menino Welcomes EvaluatePharma to Boston - Boston Redevelopment Authority, November 10, 2010
"Mayor Thomas M. Menino and the Boston Redevelopment Authority welcomed EvaluatePharma USA, Inc. to Boston’s biotech community at the opening of their new U.S. headquarters.." more...
September 2010
Betting the pharma - Astellas GC Jerry Temko on the 'perfect storm' in the pharmaceuticals industry - Legalweek.com, September 1, 2010
"...according to...Evaluate Pharma, around half of the $383bn (£255bn)-worth of patented drugs sold worldwide last year will lose patent protection in the next five years..." more...
August 2010
Multiple Remedies Needed To Heal Europe's Pharma Giants - Wall Street Journal, August 25, 2010 [subscription only]
"...According to...EvaluatePharma Ltd., annual R&D spending growth at the world's 10 largest firms is set to fall to 2.3% from 2009 to 2016..." [subscription only]
Teva Completes ratiopharm Acquisition and Becomes the Largest Euroopean Generics Company - EuroPharma Today, August 11, 2010
"Evaluate Pharma, in an analysis published in May this year, indicated that by 2016, Teva could well be one of the top-10 pharmaceutical companies in the world, ahead of more conventional big pharma companies like Bristol-Myers Squibb, Lilly and Amgen." more...
Gastroenterologists “prescribing Humira off-label for ulcerative colitis” - PharmaTimes online, August 9, 2010
"...a recent study by EvaluatePharma forecasts that by 2016 [Humira] will be the world’s top-selling drug, with sales growing 9% a year to total $10.1 billion in that year" more...
The Commercial Chemist - Chemistry World's round-up of money and molecules - Chemistry World blog, August 4, 2010
"According to pharmaceutical analysis company EvaluatePharma, two key shareholders with a combined stake of 38.9 per cent have already agreed to sell their shares to Shire." more...
Big Pharma Won't Wait in Rush for Biotech's Drugs - Wall Street Journal, August 4, 2010 [subscription only]
"...The average upfront payment for a Phase I asset was 68% higher in 2009 than a year earlier at $46 million and 39% higher at $37 million for a phase II product, according to data from research firm EvaluatePharma." [subscription only]
Alternative biologics set to shake up RA market - PharmaTimes online, August 3, 2010
"Second-quarter sales of Humira...rose 21.5% to $1.59 billion, Abbott reported last month, and analysts at EvaluatePharma recently forecast that it will be the world's top-selling drug by 2016..." more...
July 2010
Actos Cashes In On Avandia Safety Concerns - Pharmaceutical Technology Magazine, July 30, 2010
"Sales of [Actos] have risen from $2.8 billion in 2006 to $3.8 billion in 2008, according to EvaluatePharma." more...
The Research Revolution - Pharmiweb.com, July 19, 2010
"...according to data acquired from EvaluatePharma, the industry is set to lose up to $58bn in global sales from patent expirations in 2011, as blockbuster drugs such as Singulair (Merck), Lipitor (Pfizer) and Nexium (AstraZeneca) all lose their patents." more...
At EuroBiotech, Teva The Contender - The IN VIVO Blog, July 7, 2010
"Teva's net margin was 21.8 percent in 2009 and analysts project it will be 25.7 percent this year, compared to 23.6 percent for Big Pharma's group average, according to a consensus analysis by EvaluatePharma..." more...
Big Pharma's Most Feared Competitor - PharmExec.com.com, July 1, 2010
"According to the recent "World Preview Report" by EvaluatePharma, which one of the following will be among the top ten pharmaceutical companies, ranked by sales, in the year 2016: A) Bristol-Myers Squibb, B) Teva, C) Amgen, or D) Genzyme? The answer, you may be surprised to learn, is Teva Pharmaceuticals..." more...
June 2010
Innovaro Facilitates the Licensing of Trojantec Infectious Diseases Technology - MarketWatch, June 10, 2010
"Global sales of vaccines and anti-viral drugs reached $48 billion in 2009 and, according to EvaluatePharma(R), are expected to be $70billion by 2016." more...
Head-to-head trials could threaten Roche Lucentis franchise in AMD - The Pharmaletter, June 1, 2010 [subscription only]
"According to...EvaluatePharma’s EP Vantage, [Roche] could receive a definitive answer in 2011 [about the future of the Lucentis (ranibizumab injection) ophthalmology franchise] as at least half a dozen ongoing head-to-head trials begin to report data. .." more... [subscription only]
May 2010
EvaluatePharma estimates $785 billion worldwide sales in 2016 - Pharmaceutical Commerce, May 28, 2010
"Pharmaceutical companies fared better than predicted in 2009, according to EvaluatePharma’s World Preview 2016. The worldwide market grew 2.6%..." more...
Blockbusters - alive and well - Pharmaceutical Executive Digest Europe, May 26, 2010
"[EvaluatePharma's World Preview 2016]...shows, among other things, that the blockbuster is far from dead..." more...
Study shows impending churn in the pharma industry - Daily News & Analysis, May 7, 2010
"New York-headquartered Pfizer will remain the world’s top pharmaceutical company six years from now...a study titled World Preview 2016 by pharma and biotech industry consulting firm EvaluatePharma reveals..." more...
Who Will Be Pharma's Top Dog in 2016? - Pharmaceutical Technology, May 6, 2010
"The year 2016 will see Pfizer (New York) continue to cling to first place on the Top 10 pharma list, but just barely, with Merck & Co. (Whitehouse Station, NJ) and Novartis (Basel, Switzerland) not far behind. A few major patent decisions or further mega-mergers could topple the pharmaceutical giant from its coveted perch, according to analysis from EvaluatePharma...." more...
Humira to be largest selling drug with $10 bn sales; Teva among top 10 by 2016 - Dances with Shadows - Pill Scribe, May 5, 2010
"Abbott’s Humira to treat rheumatoid arthritis will be the top-selling drug with a sales of about $10.1 billion by the year 2016, according to a new forecast World Preview 2016 report published by EvaluatePharma..." more...
Looking into the future of drug sales - The Day, May 5, 2010
"Projected drug sales compiled by EvaluatePharma...show Pfizer's top medicine (No. 3 worldwide) will be arthritis remedy Enbrel..." more...
Pfizer will reign supreme after “patent cliff,” as Humira kicks Avastin off top spot, says EvaluatePharma - The Pharmaletter, May 4, 2010 [subscription only]
"US drug major Abbott Laboratories’ and Japanese firm Eisai’s rheumatoid arthritis treatment Humira (adalimumab) will replace global behemoth Pfizer’s Lipitor (atorvastatin) as the world's biggest-selling drug in 2016, but a familiar name, Pfizer, will still be the biggest seller of medicines after the patent cliff, according to the World Preview 2016 report from EvaluatePharma..." more... [subscription only]
What's behind Humira's bullish forecast? - Medical Marketing & Media, May 4, 2010
"According to the forecast, by EvaluatePharma, Humira will become the top-selling anti-TNF - and the world's biggest product - in 2012..." more...
Abbott, Teva Emerge as Winners After Patents Expire - Portfolio.com (blog), May 3, 2010
"...Pfizer will remain the top company for overall drug revenue, while Israeli generics maker is slipping into the top 10, according to EvaluatePharma...." more...
Humira elbows Avastin aside in top-drug ranking - FiercePharma, May 3, 2010
"...Market researchers EvaluatePharma have crunched the numbers on big-drug sales growth, and while their conclusions might not make Roche super-happy, ..." more...
Pharma outlook - 2016 - cafepharma, May 3, 2010
"...In conjunction with the BIO convention, [EvaluatePharma] has made predictions on the pharma landscape for 2016..." more...
Prolia is Most Valuable R&D Asset; Humira is No. 1 Drug - The IN VIVO Blog, May 3, 2010
"Evaluate Pharma is one of numerous pharma consulting firms to publish its own sweep of the biopharma industry in conjunction with BIO..." more...
Prediction: Lipitor to Cede the 'Best-Selling' Crown to Humira - Wall Street Journal (blog), May 3, 2010
"Humira is one of three RA [rheumatoid arthritis] drugs that will make the top ten, says...EvaluatePharma." more...
Abbott's Humira to Top Avastin as Best-Selling Drug - Bloomberg, May 3, 2010
"Revenue from Humira will increase about 9 percent annually to $10.1 billion in 2016 from $5.6 billion in 2009, London-based EvaluatePharma said..." more...
Humira To Be Top World Drug In 2016, Beating Avastin - Wall Street Journal, May 2, 2010 [subscription only]
"...EvaluatePharma predicts US-based Pfizer, through a strategy of mergers and acquisitions including last year's $68 billion merger with Wyeth, will cling to the top spot in prescription sales..." more... [subscription only]
April 2010
Moving to the Next Level in Biomanufacturing - Pharmaceutical Technology, Apr 2, 2010
"...Evaluate Pharma projects that biologics will account for 50% of the top 100 drugs in 2014, compared with 28% in 2008..." more...
March 2010
PPD launches centre of excellence for vaccines, biologics - PharmaTimes, Mar 25, 2010
"According to EvaluatePharma, the compound annual growth rate of biologics is projected at 8.5% from 2008 to 2014, eight to 10 times greater than the growth rate for small-molecule drugs." more...
February 2010
Biopharmaceuticals: saving the future of our industry - Pharmaceutical Technology Europe, Feb 1, 2010
"...market analysis firm EvaluatePharma has predicted that the top six selling drugs of 2014 will be biotech products, compared with only five in 2008 and one in 2000....In a statement, EvaluatePharma added that the "weight of evidence for a shift to biotech products as the industry's growth driver is overwhelming". more...
January 2010
Novo Hopes for a Diabetes Blockbuster - The Burrill Report, January 30, 2010
"During the last 12 months, predictions for 2010 sales of the drug [Victoza] fell to $591 million from original estimates of $951 million as concerns about potential thyroid cancer risks (based on rodent data) came to the fore, according to EvaluatePharma." more...
December 2009
Risky business - Economist, December 31, 2009
"In 2009, $26 billion of [prescription drug] sales were at risk from patent expiries. This will nearly double in 2011 according to EvaluatePharma..." more...
September 2009
Deals of the Week: Behold the Reimbursement Milestone - The IN VIVO Blog, September 25, 2009
"If the deal [with Leo Pharma] gets Warner out of debt faster...EP Vantage says it’s “reasonably priced” for Leo... EP Vantage notes the deal could be considerably more expensive, however if the acquired pipeline fails to pan out..." more...
Evaluate Ltd receives Queen's Awards for Enterprise: International Trade, 2009 - September 24, 2009
On September 24, 2009, Evaluate Ltd was formally presented with the Queen's Awards for Enterprise: International Trade 2009, by Deputy Lieutenant of London, Commander John Ludgate, in a ceremony at Christchurch, Spitalfields. more...
Glaxo Search for Acquisitions Hampered by 'Desperate' Rivals - Bloomberg, September 24, 2009
"USA Drugs generating $187 billion in sales are threatened by generics between 2011 and 2014 as patents expire, according to EvaluatePharma..." more...
Trust is more than a marketing issue - Pharmaceutical Executive Digest Europe, September 16, 2009
"I...was amazed to discover from the EvaluatePharma database that within less than a week of the first swine flu deaths in April, a staggering $23.2 billion had been added to the value of the world's top anti-viral drugmakers..."more...
EvaluatePharma: Generic players impress in the first half - Generics & Biosimilars Initiative Online, September 14, 2009
"A new analysis of net margins by EvaluatePharma tagged companies for profitability, and the winner was not one of the big pharma companies..."more...
August 2009
PREVIEW-Astra, Boehringer may steal show at heart congress - Reuters, August 24, 2009
"...consensus risk-adjusted forecasts for 2014 Brilinta sales are just $686 million, according to...Evaluate Pharma" more...
Big drug firms embrace generics - Economist, August 6, 2009
"Evaluate Pharma...estimates that about half of the $383 billion-worth of patented drugs to be sold in the world this year will lose patent protection within five years." more...
July 2009
Does Big Pharma still exist? - Pharmaceutical Executive Digest Europe, July 22, 2009
"Figures from EvaluatePharma's World Preview 2014 show generics companies, small companies, biotech companies, any companies that aren't Big Pharma, are all still doing well relative to the performance of traditional Big Pharma." more...
Forget Brand vs. Brand - This is War! - Pharmaceutical Executive, July 1, 2009
"According to market research firm EvaluatePharma, by 2014 Roche will have the most dominant single portfolio in the pharmaceutical industry: Sales of its oncology products are projected to reach $28.3 billion, representing a massive 38 percent of the $75 billion cancer market." more...
Most profitable drugmaker? Not a Big Pharma - FiercePharma, July 1, 2009
"Which pharma is the most profitable? You might be surprised. A new analysis of net margins by EvaluatePharma tagged companies for profitability, and the winner wasn't one of the biggies." more...
June 2009
The Battle Over Biologics Begins - Taking Note, June 29, 2009
"A report from EvaluatePharma...found that “seven of the top 10 drugs in 2014 are forecast to be biotech in origin, compared to five in 2008 and just one in 2000." more...
DotW: Dollars to Donuts - The IN VIVO Blog, June 26, 2009
"...the helpful folks at EP Vantage provided some additional color on the [GSK-Chroma] tie-up..." more...
Sanofi may suffer, whatever final Lantus verdict - Reuters, June 26, 2009
"Most industry analysts expect Lantus to generate sales of around $4 billion this year and consensus forecasts compiled by EvaluatePharma suggest this will rise to $6.4 billion in 2014..." more...
Redefining Pharma - Biotechnology products will dominate industry’s growth - The Burrill Report, June 21, 2009
“EvaluatePharma predicts that biotech drugs will account for half of the 100 top selling drugs by 2014, up from just 11 percent in 2000.”...more...
Top 6 drugs tipped to be biotech products by 2014 - Reuters, June 17, 2009
"Seven of the top ten drugs will be biopharmaceuticals by 2014 according to sector analysts Evaluate Pharma." more...